Aktie 1795 LOTUS PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Lotus Pharmaceutical Co., Ltd. Taipei Exchange

Aktien

1795

TW0001795003

1795

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 13.12.2019 		% 5 Tage % 1. Jan.
108 TWD +0,47 % Intraday Chart für Lotus Pharmaceutical Co., Ltd. -4,42 % -.--%
11.05. Lotus Pharmaceutical Co. Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
26.03. Lotus Pharmaceutical Co., Ltd. gibt den Wechsel des Vertreters des institutionellen Direktors des Unternehmens bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Lotus Pharmaceutical Co., Ltd. Announces the Appointment of Valerie Lau as APAC Chief Commercial Officer, Effective February 15, 2024
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth
Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.
Lotus Pharmaceutical Co., Ltd. Announces Director Changes
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
Lotus Pharmaceutical Co., Ltd. Appoints Susan Liao as Acting Spokesperson
Lotus Pharmaceutical Co., Ltd. Announces Appointment of the Remuneration Committee Members
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 1795 Aktie
  4. 1795 Aktie
  5. Nachrichten Lotus Pharmaceutical Co., Ltd.
  6. Andere Sprachen